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a b s t r a c t 
The data presented in this article is related with the re- 
search paper entitled “Evaluation of MGP gene expression 
in colorectal cancer”, available on Gene journal [1] . From all 
the transcription factors known to regulate MGP , FGF2 is the 
most described in colon adenocarcinoma and colon tumor 
cell lines, where it was shown to: i) contribute for the in- 
vasiveness potential; and ii) promote proliferation and sur- 
vival of colorectal cancer cells. These in vitro studies pose the 
hypothesis that FGF2 associated signaling pathways could be 
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promoting the regulation of others genes, such as MGP, that 
may lead to tumor progression which ultimately could result 
in poor prognosis in colon adenocarcinoma. 
© 2020 The Author(s). Published by Elsevier Inc. 
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F  pecifications Table 
Subject Molecular biology 
Specific subject area Colorectal cancer, Molecular biology 
Type of data Table 
Graph 
Figure 
How data were acquired qRT-PCR, SPSS 
Data format Raw 
Analysed 
Parameters for data collection FGF2 was shown to be both a regulator of MGP and an inhibitor of cellular 
differentiation in colorectal cancer organoids and FGF family proteins were 
proven to have an important role on the survival and growth of stem cells 
during embryogenesis, carcinogenesis and tissue regeneration 
Description of data collection FGF2 gene expression analysis through qRT-PCR and assessment of the 
correlation with MGP gene expression and clinical and histopathological data 
analysis using SPSS software in colorectal patients 
Data source location University of Algarve 
Faro 
Portugal 
Data accessibility Data is available with this publication 
Related research article Caiado, H. et al. 2019 
Evaluation of MGP gene expression in colorectal cancer 
Gene 
doi.org/10.1016/j.gene.2019.144120 
alue of the Data 
• The data presented here were obtained in order to evaluate FGF2 gene expression in patients
with colorectal cancer. This data may be of great relevance in trying to understand how MGP
gene expression deregulation may affect patient ́s prognosis. 
• Beneficiaries of these data are all those who seek knowledge about the molecular mecha-
nisms that could be underlying MGP deregulation in tumorigenesis. 
• These data report the upregulation of FGF2 gene expression in tumor tissue and its positive
correlation with MGP gene expression in CRC. These results could provide future insights for
the search of new therapeutic targets associated with MGP gene expression and its deregula-
tion in cancer. 
. Data Description 
The fibroblast growth factor (FGF) signaling network has been implicated in several path-
ays, such as normal cell growth, differentiation, angiogenesis and tumor development [2] . The
ranscription factor FGF2 is one of the most studied in terms of its role in carcinogenesis includ-
ng its role in tumor cell differentiation and proliferation [2] . Moreover, it is known that FGF2
nduces transcription of the MGP gene [3] . 
In this report, we describe data regarding the expression analysis performed by qRT-PCR for
GF2, for both normal and tumor tissues, of 23 out of 33 CRC patients [1] whose samples were
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Table 1 
Demographic features of colorectal patients 
MGP (n = 23) FGF2 (n = 23) 
Characteristics Number (%) 
Mean value 
of fold 
change p value Number (%) 
Mean value 
of fold 
change p value 
Gender 0.033 0.439 
Male 14 (61) 3.135 14 (61) 2.0 0 0 
Female 9 (39) 6.648 9 (39) 1.0 0 0 
Age (median: 71,70 years) 0.548 0.776 
< 72 8 (35) 2.898 8 (35) 4.437 
≥72 15 (65) 5.369 15 (65) 5.640 
Familial Cancer History 0.671 0.579 
Yes 7 (30) 3.034 7 (30) 3.495 
No 16 (70) 5.155 16 (70) 5.977 
Previous Pathologies 0.691 1.0 0 0 
Yes 18 (78) 3.732 18 (78) 5.460 
No 5 (22) 7.308 5 (22) 4.363 
Metastasis 0.177 0.812 
Yes 6 (26) 8.082 6 (26) 5.445 
No 17 (74) 3.249 17 (74) 5.143 






























still available, and 9 samples from the control group ( Fig. 1 ). The data showed that the expres-
sion of FGF2 was significantly up-regulated in CRC tissues compared to matched normal tissues
(p = 0.002). Our data is in accordance with what was already described in the literature regarding
the increase of FGF2 expression in various tumor tissues, such as lung [4] , colorectal [5] , bladder
[6] and prostate [7] . 
To evaluate if there is a correlation between FGF2 expression and the clinical-pathological
features of the patients, we analyzed all the variables shown in Tables 1 and 2 . No statistically
significant associations were found between FGF2 expression and the clinical and pathological
features of the patients. 
We then evaluated the correlation between FGF2 and MGP expression. FGF2 mRNA expression
determined by qRT-PCR was well correlated (r = 0.572, p = 0.004) with that determined for MGP
[1] ( Fig. 2 ). 
In our previously published study, we found that the two step cluster analysis of the CRC
samples allowed differentiating patients with a better or worse survival outcome [1] . Subse-
quently, we performed a multivariate classification of two step clusters [8] to determine pos-
sible patient profiles, taking into account the characteristics of categorical and numerical vari-
ables ( Table 3 ). This type of analysis allows the exploitation of data taking into account each
variable independently from each other’s, to try to identify homogeneous groups depending on
their characteristics. Since we did not find any correlation between the high expression of FGF2
and the overall patient survival rate ( Fig. 3 ), we then evaluated the prognostic value of different
variables to differentiate patients in different groups according to the influence of these factors.
The variables considered were: T classification, N classification, tumor staging, gender, deceased,
fold change MGP categorized, fold change FGF2 categorized, fold change MGP , fold change FGF2 ,
tumor histology, KRAS mutations, tumor location, survival rate (months), polyposis and stroke.
According to this analysis, patients were divided into clusters 1 and 2. Patients in cluster 1 pre-
sented a stage N0 of lymph node metastasis (50%), the tumor was either in stage II (33.3%)
or stage III (44.4%), mostly male (72.2%), with low MGP (72.2%) and FGF2 (55.6%) levels of ex-
pression, with a fold change for MGP of 3.09 ( ±3.03) and for FGF2 of 4.89 ( ±6.81), with a tu-
mor histology showing either a moderately (44.4%) or well differentiated tumor (44.4%), without
mutation on KRAS (61.1%), with a T3 classification (72.2%), with a mean survival time of 49.61
( ±18.6) months, with the tumor mostly located in rectum (38.8%) and without the presence of
polyposis (88.9) and no stroke (88.9%). Patients in cluster 2 presented a stage N1 of lymph node
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Fig. 1. Relative MGP and FGF2 gene expression in samples from patients with colon adenocarcinoma. Relative MGP (A) 
and FGF2 (B) gene expression levels were analyzed by q RT-PCR in a total of 9 samples from control group and 23 samples 
from colorectal cancer tissue (normal and tumor mucosa). The latter showed higher mRNA levels of MGP and FGF2 than 
non-tumor tissues ( MGP p = 0.002; FGF2 p ≤0.001). Values are presented as mean ± SD. The Mann-Whitney and Kruskal 
Wallis non parametric tests were performed for the statistical analysis. 
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Table 2 
Histopathological features of patients 
MGP (n = 23) FGF2 (n = 23) 
Characteristics Number (%) 
Mean value of 
fold change p value Number (%) 
Mean value of 
fold change p value 
Tumor Location 0.618 0.493 
Rectum 12 (52) 4.672 12 (52) 3.967 
Rectosigmoid Junction 3 (13) 6.217 3 (13) 2.479 
Ascending Colon 2 (9) 2.633 2 (9) 10.730 
Sigmoid 1 (4) 8.004 1 (4) 3.653 
Cecum 2 (9) 2.793 2 (9) 14.938 
Hepatic Angle 3 (13) 3 (13) 
Tumor Histology 0.196 0.655 
Well Differentiated 10 (44) 4.014 10 (44) 3.400 
Moderately Differentiated 9 (39) 2.164 9 (39) 7.867 
Poorly Differentiated 1 (4) 24.042 1 (4) 5.530 
Mucinous 1 (4) 8.004 1 (4) 3.653 
Mucinous Well Differentiated 2 (9) 6.028 2 (9) 3.054 
Tumor Stage 0.201 0.336 
I - II 9 (39) 3.155 9 (39) 3.017 
III - IV 14 (61) 5.380 14 (61) 6.639 
T classification 0.815 0.447 
pT2 4 (18) 3.983 4 (18) 1.866 
pT3 18 (78) 4.763 18 (78) 5.918 
pT4 1 (4) 2.055 1 (4) 6.109 
N classification 0.372 0.592 
N0 9 (39) 3.155 9 (39) 3.017 
N1 8 (35) 5.626 8 (35) 6.717 
N2 6 (26) 5.053 6 (26) 6.536 
M classification 0.227 0.745 
M0 18 (78) 3.294 18 (78) 5.505 
M1 5 (22) 8.884 5 (22) 4.201 
Hepatic Metastasis 0.227 0.745 
Yes 5 (22) 8.884 5 (22) 4.201 
No 18 (78) 3.294 18 (78) 5.505 
Pulmonary Metastasis 0.158 0.198 
Yes 2 (9) 14.057 2 (9) 8.597 
No 21 (91) 3.600 21 (91) 4.900 
KRAS mutations 0.728 0.265 
Yes 8 (35) 4.022 8 (35) 7.826 
No 15 (65) 4.770 15 (65) 3.833 














metastasis (60%), the tumor was either in stage III (20%) or stage IV (80%), mostly female (80%),
with high MGP (100%) and FGF2 (80%) levels of expression, with a fold change for MGP of 9.61
( ±8.4) and for FGF2 of 6.38 ( ±5.0), with a well differentiated tumor histology (40%), without
mutation on KRAS (80%), with a T3 classification (100%), with a mean survival time of 18.00
( ±8.2) months, with the tumor located in rectum (100%) and without the presence of polyposis
(100%) and no stroke (100%). 
Moreover, we performed a Kaplan-Meier survival analysis to assess if MGP and FGF2 could be
in fact good prognostic factors in terms of overall survival rate for the two groups of patients
found in the two-step cluster analysis. Patients in cluster 2, which presented a worst prognosis,
had a higher mortality rate when compared with patients in cluster 1 (log-rank test p ≤0.001)
( Fig. 4 ). 
From the analysis it was perceived that patients in cluster 2 had a worst prognosis, in the
way that all of these patients presented a small survival rate, and higher tumor stages when
compared with patients in cluster 1. It’s also worthy of note, that the variables that significantly
contributed to the division of the patients were the tumor staging, the presence of high level
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Table 3 
Multivariate analysis of predictor factors 
Characteristics Cluster 1 (n = 18, %) Cluster 2 (n = 5, %) p value 
N Classification p = 0.126 1 
N0 9 (50) 0 (0) 
N1 5 (27.8) 3 (60) 
N2 4 (22.2) 2 (40) 
Tumor Staging p = 0.05 1 
Stage I 3 (16.7) 0 (0) 
Stage II 6 (33.3) 0 (0) 
Stage III 8 (44.4) 1 (20) 
Stage IV 1 (5.6) 4 (80) 
Gender p = 0.05 1 
Male 13 (72.2) 1 (20) 
Female 5 (27.8) 4 (80) 
Deceased p = 0.05 1 
No 18 (100) 0 (0) 
Yes 0 (0) 5 (100) 
Fold change MGP categorized p = 0.05 1 
High MGP 5 (27.8) 5 (100) 
Fold change FGF2 categorized 8 (44.4) 4 (80) p = 0.159 1 
High FGF2 
Fold Change MGP , mean (SD 2 ) 3.09( ±3.03) 9.61( ±8.4) p = 0.05 3 
Fold change FGF2 , mean (SD 2 ) 4.89( ±6.81) 6.38( ±5.00) p = 0.403 3 
MGP vs FGF2 5 r = 0.373; 
p = 0.128 r = -0.200; p = 0.747 
Tumor Histology p = 0.246 1 
Well differentiated 8 (44.4) 2 (40) 
Moderately differentiated 8 (44.4) 1 (20) 
Poorly Differentiated 0 (0) 1 (20) 
Mucinous 1 (5.6) 0 (0) 
Mucinous well differentiated 1 (5.6) 1 (20) 
KRAS mutations p = 0.433 1 
No 11 (61.1) 4 (80) 
T classification p = 0.412 1 
T1 0 (0) 0 (0) 
T2 4 (22.2) 0 (0) 
T3 13 (72.2) 5 (100) 
T4 1 (5.6) 0 (0) 
Survival Rate (Months), mean (SD 2 ) 49.61( ±18.6) 18.00( ±8.2) p = 0.05 4 
Tumor Location p = 0.320 1 
Rectum 7 (38.8) 5 (100) 
Rectosigmoid junction 3 (16.7) 0 (0) 
Ascending colon 2 (11.1) 0 (0) 
Sigmoid 1 (5.6) 0 (0) 
Cecum 2 (11.1) 0 (0) 
Hepatic angle 3 (16.7) 0 (0) 
Polyposis p = 0.435 1 
No 16 (88.9) 5 (100) 
Stroke p = 0.435 1 
No 16 (88.9) 5 (100) 
Boldfaced values - Variables with p ≤ 0.05 
1 Chi Square test 
2 Standard Deviation 
3 Mann-Whitney test 
4 Log Rank test 
5 Spearman coefficient correlation test 
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Fig. 2. Correlation between FGF2 and MGP gene expression in tumor tissue. As described in experimental design in 
materials and methods, the correlation between MGP and FGF2 gene expression was evaluated through the SPSS soft- 
ware, applying the Spearman coefficient correlation test in the tumor tissue and establishing a positive and significant 














of MGP , gender and the survival rate. This means that, per se, the high levels of FGF2 alone are
not sufficient for the clustering of patients, but in combination with other multiple variables can
profile the patients into groups with a better or worst prognosis. 
Despite the presence of some patients in cluster 1 presenting a T staging of 3 or even 4, this
does not mean that these patients will actually have an associated worst prognosis. In fact, it
was already shown in the literature that patients who presented a tumor stage III could have
a better prognosis than those with a tumor stage II. For example, according to the American
Joint Committee (AJCC) staging manual [9] , when TNM staging is being evaluated, the clinicians
have to take into account the tumor size (T), the number of lymph node metastasis, and the
presence of metastasis. The stage is then categorized according to the combination of those three
major factors, but the prognosis of the disease is reflected by its combination with other external
variables that may also contribute to a worst and better prognosis. The conclusion from this
analysis shows that it is the combination of the multiple variables analyzed, together with the
high expression of FGF2 in tumor tissue that can differentiate patients in two groups associated
to a better or worst prognosis. 
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Fig. 3. Overall survival curve of patients with overexpression of FGF2. Patients with high FGF2 gene expression appear 
to have a lower survival rate although this was not statistically significant (p = 0.179). Small vertical lines indicate the 
censored cases referring to the number of patients that have not reached the terminal event during the data collection. 















. Experimental Design, Materials, and Methods 
In this report we present briefly the materials and methods used to obtain the data here
escribed. To see a more detailed material and methods, please refer to [1] . 
.1. Clinical, demographic and pathological characteristics of patients 
Tissue samples, as well as clinical and pathological information, were obtained as described
n the research article “Evaluation of MGP Gene Expression in Colorectal Cancer”. 
Clinical, demographic and histopathological information regarding patients is depicted in
ables 1 and 2 . 
.2. qRT-PCR 
Total RNA was extracted from fresh biopsies stored in RNALater (CRC (n = 23) including nor-
al adjacent tissue and healthy colonic tissue (n = 9)). After quality and quantity measurements,
DNA synthesis was performed using 1 μg of the extracted RNA treated with RQ1 DNase (1U
er μg of RNA; Promega) and M-MLV reverse transcriptase (ThermoFisher Scientific) according
o manufacturer’s instructions. 
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Fig. 4. Overall survival curve for patients categorized by clusters 1 and 2. Patients in Cluster 1 present a better survival 
rate, when compared with patients in cluster 2, who have a lower survival rate and a worse prognosis. Small vertical 
lines indicate the censored cases referring to the number of patients that have not reached the terminal event during 













The expression of mRNA for FGF2 was analyzed by 2 −Ct method and normal-
ized with the expression of glyceraldehyde-3-phosphate dehydrogenase ( GAPDH ) as refer-
ence gene. Primer sequences for GAPDH and FGF2 were as follows: GAPGH : forward: 5’-
CAACGGATTTGGTCGTATTGGGCG-3’ and reverse: 5’-CTCGCTCCTGGAAGATGGTGATGGG-3’; FGF2 : 
forward: 5’-CAAAAACGGGGGCTTCTTCCTG-3’ and reverse: 5’-CCATCTTCCTTCATAGCCAGGTAACG- 
3’. 
Data were presented as the relative quantity of target mRNA normalized with GAPDH and
relative to the mean expression of the control group. Please refer to the research article “Evalu-
ation of MGP Gene Expression in Colorectal Cancer” for the analyses of expression of mRNA for
MGP [1] . 
2.3. Statistical analysis 
Statistical analysis was performed using SPSS software program version 25. Values for gene
expression are presented as mean and standard deviation (SD) and two-sided P value less than
0.05 was defined as statistically significant. Fold changes presented correspond to the ratio of
the values from tumor mucosa versus normal mucosa. Comparisons between group variables
and gene expression were estimated using non parametric statistical tests: Mann–Whitney U
and Kruskal–Wallis. 



































The cutoff value to distinguish the patients with low and high MGP and FGF2 levels were
stimated taking into account the median value of the fold change for both MGP and FGF2 . 
A multivariate classification of two step clusters [8] was performed to determine possible
atient profiles, taking into account the characteristics of categorical and numerical variables
 Table 3 ). This allowed the formation of cluster 1 (n = 18) and cluster 2 (n = 5). Spearman coef-
cients were considered to analyze the correlation between MGP and FGF2 fold change values
y the interest groups, namely, clusters and tissue samples. Overall survival probability for two
roups of patients (clusters 1 and 2) was calculated using the Kaplan–Meier method; intergroup
ifferences were determined using a log-rank test. Logistic regression analysis and χ2 analysis
ere used to evaluate the independent influence of factors on the final prognosis. 
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